Metabolically Supported Chemotherapy (MSCT) is based on the Warburg hypothesis, a phenomenon also referred to as the “Warburg effect”.

In 1924, Otto Warburg recognized that cancer cells metabolize glucose in a manner that is distinct from that of normal cells.

In contrast to the widely accepted gene oriented view on the development of cancer, which supports the proposition that the origins of cancer are genetic and that cancer primarily results from dynamic changes in the genome, the Warburg hypothesis, in its simplest form, asserts that cancer is primarily a disease of metabolic dysregulation.

MSCT is centred on interventions targeting this metabolic dysregulation of cancer cells in order to increase the effectiveness and reduce the side-effects of conventional cytotoxic treatments.